Trial Search Results

TRIAD - Treatment of Insomnia and Depression

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Duke University

Stanford Investigator(s):


  • Drug: Antidepressant
  • Behavioral: Desensitization Therapy for Insomnia
  • Behavioral: Cognitive Behavioral Therapy for Insomnia


Phase 2/Phase 3


Inclusion Criteria:

   1. Meets criteria for Major Depressive Disorder

   2. Between 18 and 75 years of age and adequately fluent in English

   3. Meets criteria for an insomnia disorder

Exclusion Criteria:

   1. Women who are currently pregnant, breast-feeding, or not using a reliable birth
   control method.

   2. People for whom the antidepressant medication(s) provided in the study is not

   3. People who have had minimum adequate trials of (or have not been able to tolerate) all
   three study medications.

   4. People with uncontrolled medical conditions.

   5. People with moderate or severe sleep disorders other than insomnia

   6. Individuals on a fixed night shift or rotating work schedule that requires a night

   7. Patients with a current principal diagnosis of a psychiatric disorder that
   necessitates treatment that is not offered in the study.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305